Trial Selection Rising

NTRK fusion

NSCLC · Therapy Not Normalized

NTRK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 11 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 10

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 11

Common snippets: EGFR exon 19 deletion | KRAS G12C | BRAF V600E

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: Medium

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT07291037 | https://clinicaltrials.gov/study/NCT02568267 | https://clinicaltrials.gov/study/NCT06758557 | https://clinicaltrials.gov/study/NCT06563999 | https://clinicaltrials.gov/study/NCT06956001 | https://clinicaltrials.gov/study/NCT06081907 | https://clinicaltrials.gov/study/NCT06074588 | https://clinicaltrials.gov/study/NCT04302025 | https://clinicaltrials.gov/study/NCT04427072 | https://clinicaltrials.gov/study/NCT05567055 | https://clinicaltrials.gov/study/NCT02920996